CTOs on the Move

Carta Healthcare

www.carta.healthcare

 
Carta empowers hospitals to personalize the delivery of care to the individual needs of each patient. Our insight here is that personalizing care is not only good from an outcome/clinical perspective (where most people focus in the context of personalization) but is also the best way to optimize operations. Currently, hospitals have to over provision their resources because they are set up to serve the generic patient; planning ahead for exactly the resources needed– no more, no less– is the best way to gain efficiency. The approach we`re advocating and enabling is to: 1) Find past patients similar to the ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
James Matheson
Chief Technology Officer Profile

Similar Companies

Stanly Regional Medical Center

Accredited by The Joint Commission, Stanly Regional is governed by a volunteer board of directors representing both Stanly and Montgomery counties. Our main campus is a 109-bed medical facility consisting of 97 general acute beds, 10 rehabilitation beds and 12 behavioral health beds. With a staff of healthcare professionals using the latest medical treatments and technology, Stanly Regional Medical Center offers advancements in cancer treatment, imaging, rehabilitation, women`s services and more. For outstanding medical care from professionals you know and trust, look no further. We`re right beside you.

HT Systems

HT Systems is a Lutz, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scryptions International

Scryptions International is a Henderson, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Triangle Chapter of the American Red Cross

Triangle Chapter of the American Red Cross is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RaNA Therapeutics

RaNA Therapeutics is pioneering the discovery of a new class of RNA-targeted medicines that selectively activate protein expression within the body`s own cells. By targeting specific genes, RaNA`s novel drugs work epigenetically to precisely upregulate the expression of beneficial proteins in order to treat or prevent disease. The company`s leadership leverages preeminent founders and advisors in the field, and the strength of its fundamental patents, technology, and know-how that underlie the discovery and development of therapeutics that selectively activate RNA. RaNA is applying its proprietary technology to rapidly advance a pipeline of novel drugs for diverse therapeutic areas, with an initial emphasis in the fields of rare genetic disorders, inflammation, oncology, metabolic diseases and neurodegenerative diseases.